Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LifeSync Corp.

This article was originally published in Start Up

Executive Summary

LifeSync is discovering that the introduction of its wireless electrocardiogram (ECG) data communication system, which eliminates the lead wires of traditional ECG systems, while not necessarily enabling remote communications, is bringing clinical and economic advantages to hospitals.

You may also be interested in...



Start-Up Previews (4/07)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: The Good News for Drug Delivery, features profiles of Aequus Biopharma, Macroflux, PharmaKodex, and Supernus. Plus these Start-Ups Across Health Care: Arterial Remodeling Technologies, LifeSync, Marinus Pharmaceuticals, and Tibion.

Start-Up Previews (4/07)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: The Good News for Drug Delivery, features profiles of Aequus Biopharma, Macroflux, PharmaKodex, and Supernus. Plus these Start-Ups Across Health Care: Arterial Remodeling Technologies, LifeSync, Marinus Pharmaceuticals, and Tibion.

Devices for a Diabetes Epidemic

With an increasing emphasis on tight glycemic control in diabetes care, innovative devices could play a big role, but diabetes is a deceptively complex market. Innovative companies need to differentiate themselves, yet not venture too far outside existing industry dynamics. As the first real-time continuous glucose monitors come to market, a handful of start-ups hopes to be ready for the second generation. Many of these are taking a side excursion into the market for in-hospital glucose monitoring, once a sleepy market but now growing rapidly as outcomes data shows reduced mortality and morbidty in intensively managed hyperglycemic hospital patients.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel